Cervenka I, Al Rahmoun M, Mahamat-Saleh Y, et al. - In a prospective cohort of women in France, researchers assessed melanoma risk in relation to menopausal hormone therapy (MHT) use. Participants were 98,995 French women aged 40–65 years. Using biennial self-administered questionnaires, MHT use was evaluated. Also, Cox proportional hazards regression models adjusted for age and skin cancer risk factors were used. Among 75,523 postmenopausal women, 444 melanoma cases were documented from 1990 to 2008. Higher melanoma risk was reported in correlation with ever use of MHT. Among past users and users of MHT containing norpregnane derivatives, the link was the strongest, although with no heterogeneity across types of MHT. In relation to treatment starting shortly after menopause, a higher risk was reported. Overall, a strong link between MHT use and melanoma risk was not supported.